Sophia Genetics SA
$ 4.96
2.27%
14 Apr - close price
- Market Cap 347,593,000 USD
- Current Price $ 4.96
- High / Low $ 5.28 / 4.73
- Stock P/E N/A
- Book Value 0.69
- EPS -1.17
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -1.10 %
- 52 Week High 5.70
- 52 Week Low 2.58
About
Sophia Genetics SA (SOPH) is a pioneering leader in data-driven medicine, focusing on advanced genomic and clinical data analytics that enhance patient outcomes. Utilizing cutting-edge machine learning algorithms, the company provides a comprehensive platform that aids hospitals and laboratories in interpreting complex genomic data, thus facilitating personalized treatment strategies, especially in oncology, rare diseases, and hereditary disorders. With a strong international footprint and strategic partnerships with premier healthcare organizations, Sophia Genetics is committed to transforming healthcare through precision medicine, solidifying its position as a front-runner in the genomics landscape.
Analyst Target Price
$7.67
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-11-04 | 2025-08-04 | 2025-05-05 | 2025-03-03 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-03-05 | 2023-11-07 | 2023-08-08 | 2023-05-09 |
| Reported EPS | -0.1707 | -0.3 | -0.2457 | -0.2601 | -0.1199 | -0.2778 | -0.23 | -0.21 | -0.37 | -0.21 | -0.33 | -0.31 |
| Estimated EPS | -0.22 | -0.23 | -0.22 | -0.195 | -0.15 | -0.23 | -0.28 | -0.27 | -0.27 | -0.32 | -0.31 | -0.32 |
| Surprise | 0.0493 | -0.07 | -0.0257 | -0.0651 | 0.0301 | -0.0478 | 0.05 | 0.06 | -0.1 | 0.11 | -0.02 | 0.01 |
| Surprise Percentage | 22.4091% | -30.4348% | -11.6818% | -33.3846% | 20.0667% | -20.7826% | 17.8571% | 22.2222% | -37.037% | 34.375% | -6.4516% | 3.125% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SOPH
2026-04-11 08:09:09
SOPHiA GENETICS (NASDAQ:SOPH) President Ross Muken sold 2,786 shares totaling $13,484.24 on April 8th, as part of a Rule 10b5-1 trading plan to cover tax withholding on vested awards. This sale, alongside other recent dispositions, reduced his stake by 0.40%. The company's stock is trading at $4.70, with a market cap of $321.90 million, and recently reported an EPS miss; analysts currently rate SOPHiA GENETICS as "Hold" with a $7.00 price target.
2026-04-10 22:09:09
SOPHiA GENETICS CEO Jurgi Camblong sold 2,800 shares of company stock for $13,552.00 on April 8th, part of a series of transactions between March and April to cover tax obligations on vested equity awards under a Rule 10b5-1 plan. Despite these insider sales, which are considered routine, the stock traded down slightly, and the company reported an EPS miss with continued unprofitability. Institutional investors like UBS Asset Management and Akre Capital Management significantly increased their holdings, while analysts hold a "Hold" consensus rating with a $7 price target.
2026-04-10 22:09:09
Philippe Menu, an insider at SOPHiA GENETICS (NASDAQ:SOPH), sold 2,800 shares of the company's stock on April 8th, along with additional shares on other recent dates, as part of a pre-arranged Rule 10b5-1 plan to cover tax withholding. These sales, totaling over $13,552, represent a minor reduction in his overall holdings, which are still valued at over $1.3 million. Despite recent institutional buying and analyst "Buy" ratings, the company faces challenges including negative earnings, low margins, and increased short interest.
2026-04-10 22:09:09
SOPHiA GENETICS (NASDAQ:SOPH) insider Zhenyu Xu sold 2,800 shares worth $13,552 at $4.84 on April 8th as part of a pre-arranged Rule 10b5-1 plan to cover tax withholding. This sale reduced his position by 0.43%, though he still holds 642,152 shares valued at approximately $3.11 million. The company's stock is trading around $4.70, with institutional investors showing accumulation, analyst buy ratings, and an average price target of $7, despite recent EPS misses and negative margins.
2026-04-10 21:09:09
Manuela Valente, an insider at SOPHiA GENETICS (NASDAQ:SOPH), sold 3,824 shares on April 8th for $4.85 per share, totaling $18,546.40, as part of a Rule 10b5-1 plan to cover tax withholdings from vested equity awards. This sale reduced her holdings by 1.74% to 215,451 shares. The company recently missed earnings per share estimates, and analysts currently have a "Hold" rating on the stock with a consensus target price of $7.00.
2026-04-10 21:09:09
SOPHiA GENETICS (NASDAQ:SOPH) insider Well Daan Van sold 2,861 shares of the company's stock for $13,875.85 on April 8th, under a pre-arranged Rule 10b5-1 plan to cover tax withholding obligations. This sale reduced his ownership by 0.81%. The company recently reported a ($0.28) EPS miss, though revenue slightly exceeded expectations, and analysts currently have a "Hold" rating with a $7.00 price target.
